• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP

expresspharmaJuly 12, 2021

Tag: Unichem , Januvia , Sitagliptin

Unichem Laboratories has received tentative approval for ANDA of Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (USFDA) for a generic version of Januvia (sitagliptin) tablets, 25 mg, 50 mg, and 100 mg, of Merck Sharpe and Dohme Corp (Merck).

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The product will be commercialised from Unichem’s Goa Plant on receipt of full approval.

Previous:Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes

Next:ICMR proposes clinical trial along with Oxford University to evaluate COVID-19 therapy

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

sitagliptin intermediate 1

sitagliptin intermediate 1
Sitagliptin Phosphate

Sitagliptin Phosphate
Factory supply sitagliptin Cas 486460-32-6 from China

Factory supply sitagliptin Cas 486460-32-6 from China
Sitagliptin Phosphate + Metformin

Sitagliptin Phosphate + Metformin
SITAGLIPTIN PHOSPHATE MONOHYDRATE

SITAGLIPTIN PHOSPHATE MONOHYDRATE
Sitagliptin Base/ Phosphate

Sitagliptin Base/ Phosphate
Sitagliptin phosphate; 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)Butyl]-5,6,7,8-tetrahydro-3-(t

Sitagliptin phosphate; 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)Butyl]-5,6,7,8-tetrahydro-3-(t
Sitagliptin Triazole Hydrochloride

Sitagliptin Triazole Hydrochloride
Sitagliptin Impurity 33

Sitagliptin Impurity 33
98.5% up by HPLC Sitagliptin Phosphate 654671-78-0/ 654671-77-9

98.5% up by HPLC Sitagliptin Phosphate 654671-78-0/ 654671-77-9

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service